PT1900362E - Derivados de alfa-aminoamida úteis no tratamento de perturbações aditivas - Google Patents
Derivados de alfa-aminoamida úteis no tratamento de perturbações aditivas Download PDFInfo
- Publication number
- PT1900362E PT1900362E PT07022078T PT07022078T PT1900362E PT 1900362 E PT1900362 E PT 1900362E PT 07022078 T PT07022078 T PT 07022078T PT 07022078 T PT07022078 T PT 07022078T PT 1900362 E PT1900362 E PT 1900362E
- Authority
- PT
- Portugal
- Prior art keywords
- benzylamino
- propanamide
- fluorobenzyloxy
- cocaine
- methyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 239000003814 drug Substances 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 12
- -1 3-Chlorobenzyloxy Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 229960004502 levodopa Drugs 0.000 claims description 5
- JEARPZLCKWXTFT-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-2-methylpropanamide Chemical compound C1=CC(CNC(C)(C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 JEARPZLCKWXTFT-UHFFFAOYSA-N 0.000 claims description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000911 benserazide Drugs 0.000 claims description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 229960004205 carbidopa Drugs 0.000 claims description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 3
- AHMWTDOZNQOCAI-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC=C(F)C=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F AHMWTDOZNQOCAI-UHFFFAOYSA-N 0.000 claims description 2
- SUAPKJRANCSCBZ-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC=C(F)C=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 SUAPKJRANCSCBZ-UHFFFAOYSA-N 0.000 claims description 2
- UZUNVRHFYYUUJH-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F UZUNVRHFYYUUJH-UHFFFAOYSA-N 0.000 claims description 2
- RBPLIQLNWOKJFW-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 RBPLIQLNWOKJFW-UHFFFAOYSA-N 0.000 claims description 2
- JCIZOFILWMNHSB-UHFFFAOYSA-N 2-[[4-[(2-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC=C1Cl JCIZOFILWMNHSB-UHFFFAOYSA-N 0.000 claims description 2
- JYXHMCQBDXKJFB-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methyl-methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(N)=O)N(C)CC(C=C1)=CC=C1OCC1=CC=CC=C1F JYXHMCQBDXKJFB-UHFFFAOYSA-N 0.000 claims description 2
- KWMDBCXQGPZBCB-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F KWMDBCXQGPZBCB-UHFFFAOYSA-N 0.000 claims description 2
- ALWXTQNAGVDEMX-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC=C1F ALWXTQNAGVDEMX-UHFFFAOYSA-N 0.000 claims description 2
- HYRAJPATCBQKCF-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide Chemical compound C1=CC(CNC(CO)C(=O)N)=CC=C1OCC1=CC=CC=C1F HYRAJPATCBQKCF-UHFFFAOYSA-N 0.000 claims description 2
- WGXNRJBCPJAUOL-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-n-methylpropanamide Chemical compound C1=CC(CNC(C)C(=O)NC)=CC=C1OCC1=CC=CC=C1F WGXNRJBCPJAUOL-UHFFFAOYSA-N 0.000 claims description 2
- MODFUWXCNUBNKW-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-(3-fluorophenyl)acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 MODFUWXCNUBNKW-UHFFFAOYSA-N 0.000 claims description 2
- UGAZPYAMTAVKDF-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 UGAZPYAMTAVKDF-UHFFFAOYSA-N 0.000 claims description 2
- XWCJJIVVFMWOQA-UHFFFAOYSA-N 2-[[4-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n,2-dimethylpropanamide Chemical compound C1=CC(CNC(C)(CO)C(=O)NC)=CC=C1OCC1=CC=CC(C#N)=C1 XWCJJIVVFMWOQA-UHFFFAOYSA-N 0.000 claims description 2
- QNGQPQCXSOZZQG-UHFFFAOYSA-N 2-[[4-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC(C#N)=C1 QNGQPQCXSOZZQG-UHFFFAOYSA-N 0.000 claims description 2
- CYZUAXYGTDLCAW-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl-methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(N)=O)N(C)CC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 CYZUAXYGTDLCAW-UHFFFAOYSA-N 0.000 claims description 2
- HCSMEIBTXUDXFF-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 HCSMEIBTXUDXFF-UHFFFAOYSA-N 0.000 claims description 2
- HAQWBSZODRWECB-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC(F)=C1 HAQWBSZODRWECB-UHFFFAOYSA-N 0.000 claims description 2
- UTIKAYGNKRMHTP-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide Chemical compound C1=CC(CNC(CO)C(=O)N)=CC=C1OCC1=CC=CC(F)=C1 UTIKAYGNKRMHTP-UHFFFAOYSA-N 0.000 claims description 2
- RLHPBZNGBNCVBL-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-n-methylpropanamide Chemical compound C1=CC(CNC(C)C(=O)NC)=CC=C1OCC1=CC=CC(F)=C1 RLHPBZNGBNCVBL-UHFFFAOYSA-N 0.000 claims description 2
- AROJRYZKACVPEC-UHFFFAOYSA-N 2-phenyl-2-[(4-phenylmethoxyphenyl)methylamino]acetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1 AROJRYZKACVPEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- JMIJOQDPXHRPOI-UHFFFAOYSA-N 3-hydroxy-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(CO)C(=O)N)=CC=C1OCC1=CC=CC=C1 JMIJOQDPXHRPOI-UHFFFAOYSA-N 0.000 claims description 2
- PPNQCSNKEHUNCF-UHFFFAOYSA-N 3-hydroxy-n-methyl-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C1=CC(CNC(CO)C(=O)NC)=CC=C1OCC1=CC=CC=C1 PPNQCSNKEHUNCF-UHFFFAOYSA-N 0.000 claims description 2
- 229940052760 dopamine agonists Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- HXJYSYZXIYIPLJ-UHFFFAOYSA-N n,3-dimethyl-2-[(4-phenylmethoxyphenyl)methylamino]butanamide Chemical compound C1=CC(CNC(C(=O)NC)C(C)C)=CC=C1OCC1=CC=CC=C1 HXJYSYZXIYIPLJ-UHFFFAOYSA-N 0.000 claims description 2
- PFZGGJTWPMATOE-UHFFFAOYSA-N n-methyl-3-phenyl-2-[(4-phenylmethoxyphenyl)methylamino]propanamide Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1CNC(C(=O)NC)CC1=CC=CC=C1 PFZGGJTWPMATOE-UHFFFAOYSA-N 0.000 claims description 2
- ARKJBLYSUDCWBM-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-2-methylpropanamide Chemical compound C1=CC(CNC(C)(C)C(N)=O)=CC=C1OCC1=CC=CC=C1F ARKJBLYSUDCWBM-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 26
- 208000024891 symptom Diseases 0.000 abstract description 5
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 208
- 229960003920 cocaine Drugs 0.000 description 104
- 238000012360 testing method Methods 0.000 description 68
- 230000004044 response Effects 0.000 description 60
- 229940079593 drug Drugs 0.000 description 45
- 238000000034 method Methods 0.000 description 29
- 241000282693 Cercopithecidae Species 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 235000013305 food Nutrition 0.000 description 20
- 229940124597 therapeutic agent Drugs 0.000 description 20
- 241000282560 Macaca mulatta Species 0.000 description 18
- 230000003542 behavioural effect Effects 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 238000012549 training Methods 0.000 description 16
- 230000009118 appropriate response Effects 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 13
- 239000000654 additive Substances 0.000 description 12
- 230000000996 additive effect Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000006742 locomotor activity Effects 0.000 description 11
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 9
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 206010013663 drug dependence Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 206010013654 Drug abuse Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 230000002787 reinforcement Effects 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 238000007405 data analysis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000011117 substance-related disease Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000022497 Cocaine-Related disease Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003014 reinforcing effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 206010012335 Dependence Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011457 non-pharmacological treatment Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 229940127250 psychostimulant medication Drugs 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000001272 cocaine abuse Diseases 0.000 description 3
- 108700023159 delta Opioid Receptors Proteins 0.000 description 3
- 102000048124 delta Opioid Receptors Human genes 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- YAIQLSGJDFUANQ-UHFFFAOYSA-N 2-(benzylamino)propanamide Chemical class NC(=O)C(C)NCC1=CC=CC=C1 YAIQLSGJDFUANQ-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000762 chronic effect Toxicity 0.000 description 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 2
- 201000006145 cocaine dependence Diseases 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960002419 flupentixol Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- SVFXPTLYMIXFRX-BBRMVZONSA-N indatraline Chemical compound C1([C@@H]2C[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 SVFXPTLYMIXFRX-BBRMVZONSA-N 0.000 description 2
- 229950008889 indatraline Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 201000000988 opioid abuse Diseases 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000012195 Reunion island Larsen syndrome Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 230000006744 dopaminergic deficit Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229950005862 lazabemide Drugs 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000011294 monotherapeutic Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940103422 stalevo Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229950011111 sumanirole Drugs 0.000 description 1
- RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04009532A EP1588704A1 (en) | 2004-04-22 | 2004-04-22 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1900362E true PT1900362E (pt) | 2011-03-09 |
Family
ID=34924693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07022078T PT1900362E (pt) | 2004-04-22 | 2005-04-19 | Derivados de alfa-aminoamida úteis no tratamento de perturbações aditivas |
| PT05736365T PT1737438E (pt) | 2004-04-22 | 2005-04-19 | Derivados de alfa-aminoamida úteis no tratamento da síndrome das pernas inquietas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05736365T PT1737438E (pt) | 2004-04-22 | 2005-04-19 | Derivados de alfa-aminoamida úteis no tratamento da síndrome das pernas inquietas |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8445513B2 (da) |
| EP (3) | EP1588704A1 (da) |
| JP (1) | JP5020069B2 (da) |
| KR (2) | KR101195819B1 (da) |
| CN (1) | CN1942179B (da) |
| AT (2) | ATE405256T1 (da) |
| AU (1) | AU2005235428B2 (da) |
| BR (2) | BRPI0509976B8 (da) |
| CA (1) | CA2563674C (da) |
| CY (2) | CY1108494T1 (da) |
| DE (2) | DE602005009162D1 (da) |
| DK (2) | DK1737438T3 (da) |
| ES (2) | ES2313330T3 (da) |
| HR (2) | HRP20080593T3 (da) |
| IL (1) | IL178732A (da) |
| ME (2) | ME02324B (da) |
| MX (1) | MXPA06012163A (da) |
| NO (2) | NO337900B1 (da) |
| NZ (1) | NZ550664A (da) |
| PL (2) | PL1737438T3 (da) |
| PT (2) | PT1900362E (da) |
| RS (2) | RS50667B (da) |
| RU (1) | RU2403030C2 (da) |
| SI (2) | SI1900362T1 (da) |
| WO (1) | WO2005102300A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| DK1423168T3 (da) | 2001-09-03 | 2006-05-15 | Newron Pharm Spa | Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse |
| EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| ES2339021T3 (es) * | 2003-08-25 | 2010-05-14 | Newron Pharmaceuticals S.P.A. | Derivados de alfa-aminoamida utiles como agentes antiinflamatorios. |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| US20080096965A1 (en) * | 2004-09-10 | 2008-04-24 | Newron Pharmaceuticals S.P.A. | (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators |
| JP2008519811A (ja) * | 2004-11-10 | 2008-06-12 | オリオン コーポレーション | 下肢静止不能症候群の治療 |
| BRPI0620239B8 (pt) * | 2005-12-22 | 2021-05-25 | Newron Pharm Spa | derivados de 2-feniletilamino. |
| JP5769923B2 (ja) * | 2006-04-03 | 2015-08-26 | テバ ファーマシューティカル インダストリーズ リミティド | レストレスレッグス症候群の治療のためのラサギリンの使用 |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| EA017123B1 (ru) * | 2006-06-19 | 2012-10-30 | Ньюрон Фармасьютикалс С.П.А. | Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| JP5440496B2 (ja) | 2007-06-15 | 2014-03-12 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 置換２−［２−（フェニル）エチルアミノ］アルカンアミド誘導体ならびにナトリウムおよび／またはカルシウムチャネル調節剤としてのこれらの使用 |
| MX2010006278A (es) * | 2007-12-11 | 2010-08-31 | Newron Pharm Spa | Proceso para produccion de 2-[4-(3- o 2-fluorobenciloxi)bencilamin o]propanamidas con un alto grado de pureza. |
| JP5736175B2 (ja) * | 2007-12-19 | 2015-06-17 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 精神障害の治療に有用なα−アミノアミド誘導体 |
| EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| EP2563355B1 (en) | 2010-04-27 | 2016-06-08 | Newron Pharmaceuticals S.p.A. | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers |
| US11278651B2 (en) * | 2018-10-17 | 2022-03-22 | Gambro Lundia Ab | Membrane and device for treating restless leg syndrome |
| CN114667963B (zh) * | 2020-12-24 | 2024-04-26 | 中国科学院脑科学与智能技术卓越创新中心 | 一种非人灵长类动物药物成瘾性评估的装置 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
| US4049663A (en) | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
| US4970200A (en) | 1988-03-01 | 1990-11-13 | Schering Aktiengesellschaft | Agent for treatment of Parkinson's disease |
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| EP0520325A1 (de) * | 1991-06-28 | 1992-12-30 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch |
| GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| FI974323A0 (fi) | 1995-05-26 | 1997-11-25 | Pfizer | Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten |
| WO1997000511A1 (de) | 1995-06-17 | 1997-01-03 | Baumann Guenter | Scheibenkörper |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| DE19701619B4 (de) * | 1997-01-17 | 2007-10-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Pramipexol zur Behandlung des restless legs syndroms |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| GB9727521D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| EP1047756A2 (en) | 1998-01-12 | 2000-11-02 | Deborah Wenzel | An additive composition also used as a fuel composition comprising water soluble alcohols |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| AU1359801A (en) * | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
| WO2001041763A1 (en) * | 1999-12-10 | 2001-06-14 | University Of Cincinnati | Treatment of addiction disorders |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| WO2002100350A2 (en) * | 2001-06-13 | 2002-12-19 | The Regents Of University Of Michigan | Dopamine receptor ligands and therapeutic methods based thereon |
| PT1511718E (pt) * | 2002-05-29 | 2009-06-12 | Hoffmann La Roche | Derivados de n-acilaminobenzeno como inibidores selectivos de monoamina-oxidase b |
| PL203763B1 (pl) | 2002-06-24 | 2009-11-30 | Rockwool Int | Sposób i urządzenie do wytwarzania wełny mineralnej |
| US6900354B2 (en) * | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| JP2005060370A (ja) * | 2003-07-25 | 2005-03-10 | Kyowa Hakko Kogyo Co Ltd | 医薬組成物 |
| EP1524267A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Substituted benzylaminoalkylene heterocycles |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
-
2004
- 2004-04-22 EP EP04009532A patent/EP1588704A1/en not_active Withdrawn
-
2005
- 2005-04-19 RS RSP-2008/0531A patent/RS50667B/sr unknown
- 2005-04-19 NZ NZ550664A patent/NZ550664A/en not_active IP Right Cessation
- 2005-04-19 PL PL05736365T patent/PL1737438T3/pl unknown
- 2005-04-19 PT PT07022078T patent/PT1900362E/pt unknown
- 2005-04-19 AT AT05736365T patent/ATE405256T1/de active
- 2005-04-19 KR KR1020067021748A patent/KR101195819B1/ko not_active Expired - Lifetime
- 2005-04-19 EP EP07022078A patent/EP1900362B1/en not_active Expired - Lifetime
- 2005-04-19 ME MEP-2016-18A patent/ME02324B/me unknown
- 2005-04-19 CN CN2005800118905A patent/CN1942179B/zh not_active Expired - Lifetime
- 2005-04-19 SI SI200531224T patent/SI1900362T1/sl unknown
- 2005-04-19 AU AU2005235428A patent/AU2005235428B2/en not_active Expired
- 2005-04-19 KR KR1020127003440A patent/KR101238377B1/ko not_active Expired - Lifetime
- 2005-04-19 RS RS20110128A patent/RS51791B/sr unknown
- 2005-04-19 BR BRPI0509976A patent/BRPI0509976B8/pt not_active IP Right Cessation
- 2005-04-19 AT AT07022078T patent/ATE494890T1/de active
- 2005-04-19 ME MEP-2011-56A patent/ME01219B/me unknown
- 2005-04-19 DE DE602005009162T patent/DE602005009162D1/de not_active Expired - Lifetime
- 2005-04-19 DK DK05736365T patent/DK1737438T3/da active
- 2005-04-19 SI SI200530430T patent/SI1737438T1/sl unknown
- 2005-04-19 PT PT05736365T patent/PT1737438E/pt unknown
- 2005-04-19 BR BR122020004541-8A patent/BR122020004541B1/pt active IP Right Grant
- 2005-04-19 CA CA2563674A patent/CA2563674C/en not_active Expired - Lifetime
- 2005-04-19 RU RU2006137079/15A patent/RU2403030C2/ru active
- 2005-04-19 ES ES05736365T patent/ES2313330T3/es not_active Expired - Lifetime
- 2005-04-19 JP JP2007508825A patent/JP5020069B2/ja not_active Expired - Lifetime
- 2005-04-19 HR HR20080593T patent/HRP20080593T3/xx unknown
- 2005-04-19 EP EP05736365A patent/EP1737438B1/en not_active Expired - Lifetime
- 2005-04-19 PL PL07022078T patent/PL1900362T3/pl unknown
- 2005-04-19 MX MXPA06012163A patent/MXPA06012163A/es active IP Right Grant
- 2005-04-19 DE DE602005025941T patent/DE602005025941D1/de not_active Expired - Lifetime
- 2005-04-19 WO PCT/EP2005/004166 patent/WO2005102300A1/en not_active Ceased
- 2005-04-19 DK DK07022078.5T patent/DK1900362T3/da active
- 2005-04-19 US US11/578,988 patent/US8445513B2/en not_active Expired - Lifetime
- 2005-04-19 ES ES07022078T patent/ES2357559T3/es not_active Expired - Lifetime
-
2006
- 2006-10-19 IL IL178732A patent/IL178732A/en active IP Right Grant
- 2006-10-19 NO NO20064732A patent/NO337900B1/no unknown
-
2008
- 2008-11-10 CY CY20081101279T patent/CY1108494T1/el unknown
-
2011
- 2011-03-04 CY CY20111100255T patent/CY1111656T1/el unknown
- 2011-03-30 HR HR20110230T patent/HRP20110230T1/hr unknown
-
2013
- 2013-03-15 US US13/835,445 patent/US8697738B2/en not_active Expired - Lifetime
-
2015
- 2015-07-27 NO NO20150971A patent/NO338870B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8697738B2 (en) | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | |
| Bruijnzeel et al. | Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats | |
| US20020037925A1 (en) | Treatment of addiction and addiction-related behavior | |
| Bechtholt et al. | Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats | |
| HUP0303983A2 (hu) | Peptidvegyületek új alkalmazása az allodynia vagy más krónikus vagy fantom típusú fájdalom kezelésére | |
| Nemeth et al. | Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study | |
| US20020042446A1 (en) | Treatment of addiction and addiction-related behavior | |
| Reichel et al. | Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior | |
| Karami et al. | Sulpiride injections into the medial septum reverse the influence of intra-medial septum injection of L-arginine on expression of place conditioning-induced by morphine in rats | |
| Kantak et al. | Modulation of the discriminative stimulus and rate-altering effects of cocaine by competitive and noncompetitive N-methyl-D-aspartate antagonists | |
| Grubb et al. | Cocaine self-administration alters the locomotor response to microinjection of bicuculline into the ventral tegmental area of rats | |
| Allen | Continuous exposure to dizocilpine facilitates escalation of cocaine consumption in male Sprague–Dawley rats | |
| HK1099216B (en) | α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | |
| Sorge | The effects of chronic administration of Buprenorphine on intake of heroin and cocaine in rats: behavioral and neurochemical interactions | |
| TW201103546A (en) | New use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives |